Should patients receive HLA-selected platelets?

What is this research about?

Hypoproliferative thrombocytopenia (HT) occurs when production of blood platelets by the bone marrow is reduced. HT may occur in patients with leukemia, aplastic anemia or in cancer patients after chemotherapy. In patients with HT, platelets are transfused to increase the platelet count to prevent excessive bleeding.

In brief: There is a lack of convincing evidence to support the provision of HLA-selected platelets to patients. Given this knowledge gap, a multi-centre trial or study is required to compare the most commonly used approaches for HLA matching in terms of mortality or bleeding outcomes, quality of life, and economic costs/benefits.